Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Samsung commences third revocation suit against newly granted Fresenius 50mg/ml adalimumab formulation patent

Jul 29, 2022

A third revocation proceeding was commenced by Samsung Bioepis against a Fresenius Kabi adalimumab 50 mg/mL formulation patent AU2020204269 (‘269).  The ‘269 patent covers a specific formulation of adalimumab with a specific buffer, sugar, surfactant and pH.  These proceedings were commenced a day after the patent was granted (28 July 2022), following Samsung withdrawing its pre-grant opposition on 27 July (which it filed in December 2020).

Samsung commenced a revocation proceeding in June 2022 against a second, related 50 mg/mL adalimumab formulation patent.  In 2019, Samsung also sought revocation of a first Fresenius adalimumab formulation patent, which resulted in Fresenius surrendering the patent in November 2019, the proceedings being dismissed by consent, and a costs order against Fresenius being made against Fresenius.